The first signalling event in Xenopus development is the mesoderm-forming ( ; these two findings cast doubt on the idea of a function for activin in early development. We have designed a new receptor construct which can selectively block the function of activin but not of Vg1, and we have used it to show that activin has an essential role in vivo in Xenopus early development. We conclude that activin, or a close relative that has yet to be described, is required for normal development.
Previous attempts to assess the role of activin using a truncated activin type IIB receptor were deemed inconclusive when it was shown that the effects of this receptor were not specific to activin [8] : it also blocked the signalling of other TGF␤ family members, most notably Vg1. We speculated that a dominant-negative receptor which lacked a transmembrane domain might be more specific. It would still have a ligand-binding domain and therefore the ability to bind to activin and block its signalling, but might no longer be able to interfere with other receptors at the cell surface. We therefore designed a new construct consisting only of the ligand-binding domain of the activin type IIB receptor (ActRIIBexd; see Fig. 1 ). This construct differs from previous dominant-negative receptors in that it lacks both intracellular and transmembrane domains and is therefore likely to be secreted.
We determined whether our new construct can in fact block activin signalling whilst not interfering with Vg1 signalling. The animal cap assay has long been used as an assay of mesoderm induction in vitro [1] . Animal cap cells are normally fated to become ectodermal tissue, but when treated with activin or Vg1 they differentiate into mesodermal tissue. We used this assay system to test the specificity of our receptor construct. Injection of mRNA synthesized in vitro that encodes either activin or Vg1 induces a range of early mesodermal markers in animal caps (Fig. 2, lanes 3  and 6) . Addition of ActRIIBexd mRNA (exd in Fig. 2 , lane 5) blocks gene induction by activin but has no effect on gene induction by Vg1 (Fig. 2, lane 8) . We also tested two other TGF␤ family members that are candidate mesoderm inducers, Xnr1 and Xnr2 [9] . Xnr1, like activin and Vg1, induces a range of early mesodermal markers (Fig. 2, lane 
Figure 1
Composition of the ActRIIBexd dominant-negative receptor.
Comparison of the dominant-negative ActRIIBexd and ActRIIBdn [4] , the latter containing the transmembrane domain, with wild-type ActRIIB [16] . ActRIIBexd was derived from ActRIIB as described [16] , but it lacks codon 51 and differs in codon 52. However, this form of ActRIIB is known to be functionally equivalent to the published ActRIIB [16] . Numbers indicate the amino-acid residues in each construct. ) and this induction is not blocked by ActRIIBexd (Fig. 2 , lane 10). Xnr2 behaves in a similar manner (data not shown). BMP-4, another TGF␤ family member which is able to induce some mesodermal genes, was also tested. BMP-4 signalling was reduced by ActRIIBexd to only 70 % of the level seen with BMP-4 alone, under conditions in which activin signalling was less than 5 % of normal. These results clearly demonstrate that ActRIIBexd selectively blocks activin or activin-like molecules. We have further shown that ActRIIBexd is indeed more specific than a standard dominant-negative activin receptor (dn in Fig. 2 ). This previously described receptor [4] blocks signalling by activin (Fig. 2 , lane 4) and greatly reduces Vg1 signalling (Fig. 2, lane 7) . Therefore, we have generated a novel dominant-negative activin receptor which, unlike previous ones, can selectively and specifically block activin signalling.
We can now determine whether activin has a role in developing Xenopus embryos. Embryos at the 4-cell stage were injected equatorially with mRNA encoding the ActRIIBexd construct (the same dose as in the experiments shown in Fig. 2 ). These embryos were allowed to develop until the tadpole stage ( Fig. 3a,b ). The injected embryos (Fig. 3b ) appear severely defective when compared with uninjected controls (Fig. 3a) ; they lack head structures, as judged morphologically, suggesting a deficiency in anterior differentiation. We next determined ActRIIBexd is a dominant-negative receptor highly specific to activin signalling. Activin mRNA (4 pg; lanes 3-5), bVg1 mRNA (50 pg; lanes 6-8), or Xnr1 mRNA ( 500 pg; lanes 9,10) was injected into the animal pole of each blastomere of 2-cell embryos. These amounts were chosen to give an induction of early genes in animal caps equivalent to one whole embryo (we; lane 1 whether activin plays a role in mesoderm formation. There are two possible roles for activin: it could be involved either directly in the initial mesoderm induction or in the subsequent mesoderm maintenance and patterning. To distinguish between these possibilities, we investigated the effects of ActRIIBexd on the induction of Xbrachyury (Xbra), an immediate early (independent of protein synthesis) pan-mesodermal gene marker [10] . A reduction in early Xbra expression would indicate a role for activin in mesoderm induction, whereas later repression of Xbra, after its initial induction, would suggest a role for activin in mesoderm maintenance or patterning. Embryos were treated as in Figure 3b , but samples were removed at timepoints between late blastula and late gastrula stages and assayed for Xbra expression by RNase protection. These timepoints correspond to the period of initial Xbra expression [10] . The induction of Xbra when activin signalling has been blocked by ActRIIBexd appears to be delayed, compared with wild-type, by approximately half a developmental stage (1-2 hours at 23°C; see Fig. 3c ). Further analysis shows that blocking activin signalling with ActRIIBexd reduces the initial induction of Xbra (stage 9.5) to 20 % of the wild-type level (Fig. 3d) . This result indicates a role for activin in initial mesoderm induction.
The fact that wild-type levels of induction are subsequently reached between stages 10.5 and 11 ( Fig. 3d) suggests that there are mechanisms that can compensate for the lack of activin signalling but that they take time to operate. Clearly, the compensation is not sufficient to permit normal development. Degenerate or compensatory mechanisms are common in development: for example, members of the myogenic family of transcription factors are thought to be able to autoregulate their activity by binding directly to their own promoters (see [11] for review). There is also evidence that Xbra can induce expression of the eFGF gene, which can, in turn, promote the maintenance of Xbra expression [12] . In conclusion, we have shown that blocking activin signalling substantially affects embryo development, and the inhibition of early Xbra induction implicates activin in mesoderm induction.
It is striking to contrast the phenotype we obtain by blocking activin signalling ( Fig. 3b) with that obtained by blocking FGF signalling [4] . As we have shown, knocking out activin signalling generates embryos with reduced anterior structures, whilst knocking out FGF signalling gives embryos with reduced posterior structures [4] . This would suggest complementary roles for activin and FGF, with activin involved in mesoderm formation and FGF in mesoderm maintenance. It may seem surprising that follistatin, which binds to and counteracts activin, does not cause the anterior defect seen with our dominant-negative construct [13] . However, follistatin has been shown to bind to BMP-4 as well as to activin [14, 15] , and the posterior defects seen with follistatin could be due to blocking BMP-4 signalling. Furthermore, because BMP-4 has ventralizing activity, blocking BMP-4 signalling might be expected to reduce posterior structures.
To further demonstrate the role of activin in Xenopus development and the specificity of our construct, we have attempted to rescue the ActRIIBexd-injected phenotype with activin mRNA. Embryos were injected with ActRIIBexd alone, or with ActRIIBexd and increasing doses of activin mRNA, and cultured until the tadpole stage (stage 35). A low dose of activin mRNA (Fig. 4c) leads to a partial rescue of the ActRIIBexd phenotype shown in Figure 4b . A higher dose of activin mRNA completely rescues the phenotype (Fig. 4d) , comparable to the control phenotype (Fig. 4a) . These results show that activin can indeed rescue the phenotype obtained by blocking activin signalling. The dose-response nature of these results suggests that a very low concentration of activin in vivo is required for normal development. ActRIIBexd blocks this and therefore impairs normal development. Addition of exogenous activin mRNA can titrate out the effects of ActRIIBexd and, at the correct dose, rescue the embryos.
Conclusions
From the results we have presented here, we conclude that blocking activin signalling severely disrupts Xenopus development and that activin, or an activin-like molecule, does indeed play an essential role in mesoderm induction.
